-
Mashup Score: 0Gantenerumab Did Not Slow Clinical Decline as Expected in Individuals With Early Alzheimer Disease - Practical Neurology - 1 year(s) ago
In the phase 3 GRADUATE I and II studies (NCT03444870 and NCT03443973) of gantenerumab (Roche; Basel, Switzerland) for individuals with Alzheimer dise
Source: Practical NeurologyCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 5What to know about Roche’s experimental Alzheimer’s treatment - 2 year(s) ago
The next big Alzheimer’s disease study readout is almost here. Here’s what to know about gantenerumab, Roche’s experimental therapy.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1Gantenerumab Fails to Slowing Rate of Cognitive Decline in Alzheimer Disease - Practical Neurology - 4 year(s) ago
In the phase 2/3 DIAN-TU-001 study (NCT01760005), treatment with the investigational medicine gantenerumab (Genentech, San Francisco, CA) did not sign
Source: Practical NeurologyCategories: NeurologyTweet
#Gantenerumab Did Not Slow Clinical Decline as Expected in Individuals With Early Alzheimer Disease #AD #PracticalNeurology https://t.co/Z6E3vluaPi